<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703649</url>
  </required_header>
  <id_info>
    <org_study_id>Siba0101</org_study_id>
    <nct_id>NCT02703649</nct_id>
  </id_info>
  <brief_title>Administration of Single High Dose Letrozole for Ovulation Induction</brief_title>
  <official_title>Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Letrozole is considered an established treatment for ovulation induction.The most common&#xD;
      protocol is daily dose of 2.5-7.5 mg starting day 3-5 of the cycle for 5 days.Another&#xD;
      described protocol is single high dose 20mg Letrozole given on day 3 of the cycle.&#xD;
&#xD;
      Our aim is to compare the single high dose Letrozole protocol to daily low dose protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-study screening will be conducted before the enrolment in the study, routine fertility&#xD;
      assessment: Physical history including fertility and fertility treatment history. Laboratory&#xD;
      tests-cycle day 3 hormonal profile (Estradiol, Luteinizing hormone, Follicular stimulating&#xD;
      hormone, progesterone), cycle day 3 antral follicular count.&#xD;
&#xD;
      Pregnancy will be excluded by Human chorionic gonadotropin test at day 3 of the cycle, before&#xD;
      starting the fertility treatment.&#xD;
&#xD;
      Polycystic syndrome (PCOS) patients will be defined according to Rotterdam criteria 2003.&#xD;
&#xD;
      A prospective randomized clinical trial. PCOS patients who require induction of ovulation&#xD;
      will prospectively randomized into two groups:&#xD;
&#xD;
        1. Single 20 mg dose of Letrozole on day 3 of the menstrual cycle. Monitoring for response&#xD;
           will include the usual measurements of serum Estradiol (E2), Follicle stimulating&#xD;
           hormone (FSH), Luteinizing Hormone (LH), Progesterone (P) and transvaginal ultrasound&#xD;
           for follicular count and endometrial thickness measurement. First monitoring will be on&#xD;
           day 7 of the cycle and the rest of the monitoring will be determined according to&#xD;
           response.&#xD;
&#xD;
        2. Daily dose of Letrozole 2.5 mg starting day 3 for 5 days. Monitoring for response will&#xD;
           include serum Estradiol (E2), Follicule stimulating hormone (FSH), Luteinizing Hormone&#xD;
           (LH ), Progesterone (P) and transvaginal ultrasound for follicular count and endometrial&#xD;
           thickness measurement. First day of monitoring will be on day 7 and the rest of&#xD;
           monitoring will be determined according to response.&#xD;
&#xD;
      Statistical Analysis&#xD;
&#xD;
        -  Primary Endpoint Analysis: Sample Size Selection In order to prove non-inferiority with&#xD;
           significance level (alpha) 5% and power of 90%, standard deviation of outcome 1, and&#xD;
           noninferiority limit 1; the sample size needed is 36 patients in both groups.&#xD;
           Calculation based on Jolious SA formula.(7)&#xD;
&#xD;
        -  Planned Analysis&#xD;
&#xD;
      Primary Outcome Analysis:&#xD;
&#xD;
      Comparison of the number of follicle &gt;15 mm at day of ovulation&#xD;
&#xD;
      Secondary Outcome Analysis:&#xD;
&#xD;
      Pregnancy rate Comparison between the two groups Estradiol levels at day of ovulation&#xD;
      triggering Ovarian hyperstimulation syndrome Clinical pregnancy rate&#xD;
&#xD;
      Statistical analysis :&#xD;
&#xD;
      The various outcome measures will be expressed as numbers and rates. The Student t test, Ï‡2&#xD;
      test and analysis of variance will be used where appropriate to analyze the various data&#xD;
      among the study groups. P value less than .05 will be considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of follicles &gt;15 mm at day of ovulation</measure>
    <time_frame>First day of monitoring will be on day 7 and the rest of monitoring will be appointed according to response up to 1month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.</description>
    <arm_group_label>Daily dose</arm_group_label>
    <arm_group_label>Single dose</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome (PCOS) patients&#xD;
&#xD;
          -  BMI (body mass index) of 18-35.&#xD;
&#xD;
          -  Proved one patent fallopian tube at least&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with low ovarian response (According to Bologna criteria )&#xD;
&#xD;
          -  Blocked fallopian tubes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of any clinically significant health problem such that treatment with&#xD;
             letrozole or pregnancy would not be in the subject's best interest.&#xD;
&#xD;
          -  Co-administration of other anti-estrogens&#xD;
&#xD;
          -  Hypersensitivity to Letrozole .&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Casper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIO Fertility</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aromatase inhibitor</keyword>
  <keyword>induction of ovulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

